Barry Greene
Board Member
BD
Acorda Therapeutics
United States of America
Biography
Barry Greene has been a member of Acorda’s Board of Directors since January 2007. He is the President and Chief Operating Officer of Alnylam Pharmaceuticals. He joined Alnylam in September 2003, bringing more than 15 years of experience in the healthcare industry. Prior to Alnylam, Mr. Greene was General Manager of Oncology at Millennium Pharmaceuticals, Inc., where he led the company’s global strategy and execution for its oncology business, including strategic business direction and execution, which culminated in the successful approval and launch of VELCADE™ (bortezomib) in mid-2003. Before joining Millennium in February 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com. Prior to Mediconsult.com, Mr. Greene’s experience included serving as Vice President of Marketing and Customer Services for AstraZeneca, formerly AstraMerck; Vice President Strategic Integration, with responsibility for the AstraZeneca North American post-merger integration; and Partner, Andersen Consulting, responsible for the pharmaceutical/biotechnology marketing and sales practice. He currently serves on the Board of Directors of Karyopharm Therapeutics, Inc. He received his B.S. in Industrial Engineering from the University of Pittsburgh. He serves as a Senior Scholar at Duke University’s Fuqua School of Business.
Research Interest
pharmaceutical